Visit https://www.peervoice.com/FCE860 to view the entire programme with slides. After completing “Francesco Passamonti, MD - Myelofibrosis Under the Microscope: Exploring p53 Dysregulation as a Potential Therapeutic Target”, participants will be able to: Recall the cellular role of p53 in regulating apoptosis, and how this is disrupted in patients with myelofibrosis; and Assess the clinical significance of trial data evaluating the safety and efficacy of MDM2 inhibition (as monotherapy or in combination with other agents) in the therapeutic management of patients with TP53-wt myelofibrosis.

Visit https://www.peervoice.com/MQC860 to view the entire programme with slides. After completing “Steven Horwitz, MD - Relapsed/Refractory Peripheral T-Cell Lymphoma: Reviewing Available and Anticipated Strategies in This Rare Malignancy”, participants will be able to: Recognize unmet needs surrounding the management of peripheral T-cell lymphoma (PTCL), including the impact of the disease on patient quality of life (QoL); Assess the clinical significance of clinical trial data evaluating the safety and efficacy of novel treatments for the management of relapsed/refractory (R/R) PTCL; and Implement current consensus best practice approaches to the management of R/R PTCL.

Visit https://www.peervoice.com/WFR860 to view the entire programme with slides. After completing “Rachel Soyoun Kim, MD, MHSc, FRCSC - From Evidence to Practice: Combining Immunotherapy With Chemoradiotherapy Regimens in Locally Advanced Cervical Cancer”, participants will be able to: Discuss how combinations of immune checkpoint inhibitors plus chemoradiotherapy regimens may address unmet needs in patients with locally advanced cervical cancer (LACC); Evaluate the clinical significance of the latest efficacy and safety data for the combination of immune checkpoint inhibitors and chemoradiotherapy regimens in LACC; and Integrate patient-centred, multidisciplinary management strategies to enhance the care of patients with LACC.

Visit https://www.peervoice.com/USJ860 to view the entire programme with slides. After completing “Sanjay Popat, FRCP, PhD - Don’t Forget About HER2: Clinical Insights and Novel Therapies for HER2-Mutant NSCLC From ESMO 2025”, participants will be able to: Describe recent clinical trial data on novel targeted therapies for HER2-mutant NSCLC; and Evaluate recent clinical trial data on novel HER2-targeted therapies within the wider treatment landscape of NSCLC.

Visit https://www.peervoice.com/YHE860 to view the entire programme with slides. After completing “Nadia Harbeck, MD, PhD - Antibody-Drug Conjugates in Breast Cancer: Keeping Abreast of the Latest Data As They Emerge From ESMO”, participants will be able to: Evaluate emerging updates on antibody-drug conjugates (ADCs) for the treatment of HER2+ breast cancer; Recall the latest evidence for ADCs in the treatment of HR+ and/or triple-negative breast cancer; and Assess the implications of the latest clinical evidence for approved ADCs in breast cancer in context of current treatment guidelines.

Visit https://www.peervoice.com/XKC860 to view the entire programme with slides. After completing “Fred Saad, MD, FRCS - From Platform to Practice: Insights From ESMO 2025 on the Latest Data Guiding Contemporary Care in mHSPC and nmCRPC”, participants will be able to: Evaluate novel data presented at ESMO 2025 related to the use of androgen receptor pathway inhibitors (ARPIs) in the management of metastatic hormone-sensitive prostate cancer (mHSPC) and nonmetastatic castration-resistant prostate cancer (nmCRPC), including relevant efficacy and safety data, subgroup analyses, and real-world evidence; and Assess the potential implications of recently presented findings for the clinical care of individuals living with mHSPC or nmCRPC.

Visit https://www.peervoice.com/EAJ860 to view the entire programme with slides. After completing “Naveen Pemmaraju, MD - How I Treat BPDCN: A Case-Based Exploration of Best Practices in Selecting and Providing Therapeutic Strategies”, participants will be able to: Recognize guideline-recommended best practices in the diagnostic assessment and therapeutic management of patients presenting with blastic plasmacytoid dendritic cell neoplasm (BPDCN); Implement evidence-based best practice approaches to the diagnosis of BPDCN in patients presenting with symptoms of this condition; and Formulate appropriate management plans for patients with BPDCN, including selecting initial therapy, identifying candidates for stem cell transplant, and providing adverse event monitoring and management plans in patients receiving targeted therapy.

Visit https://www.peervoice.com/DHX860 to view the entire programme with slides. After completing “Alicia K. Morgans, MD, MPH - Clinical Conversations in Castration-Resistant Prostate Cancer: Best Practices in Discussing Testing and Treatment With Patients”, participants will be able to: Implement recommended patient communication approaches when discussing mutational testing in metastatic castration-resistant prostate cancer (mCRPC), including what tests involve, what impact a positive result means for treatment options, and how to empower patients to make informed decisions about their treatment plan

Visit https://www.peervoice.com/MBM860 to view the entire programme with slides. After completing “Natasha Leighl, MD, MMSc, FRCPC, FASCO - Targeting Improved Outcomes in ALK-Positive NSCLC: A Canadian Clinician’s Guide to Optimizing Outcomes Across the Spectrum of Disease”, participants will be able to: Discuss the rationale for adjuvant targeted therapy in resectable ALK-positive NSCLC; Evaluate the latest clinical data of targeted therapy in resectable ALK-positive NSCLC; and Identify patient factors to guide therapy selection in resectable NSCLC.

Visit https://www.peervoice.com/BEZ860 to view the entire programme with slides. After completing “Alison Birtle, FRCP, FRCR, MD - Case Study Challenge in Advanced Bladder Cancer: Tailoring Treatment to Individual Patients”, participants will be able to: Assess the clinical implications of clinical trial data and real-world evidence evaluating available treatment regimens for the first-line management of advanced bladder cancer; and Formulate individualised management plans for the first-line management of advanced bladder cancer considering factors such as patient age, fitness, goals of therapy and eligibility for cisplatin and carboplatin.

Visit https://www.peervoice.com/EQW860 to view the entire programme with slides. After completing “Peter Schmid, FRCP, MD, PhD - Use of Neoadjuvant Chemoimmunotherapy Followed by Adjuvant Immunotherapy in Early-Stage TNBC: A Case-Based Discussion”, participants will be able to: Identify high-risk patients with early-stage triple-negative breast cancer (TNBC) who may benefit from neoadjuvant chemoimmunotherapy, followed by adjuvant immunotherapy; Outline evidence-based, patient-centered strategies to optimally integrate neoadjuvant and adjuvant immunotherapy into practice for patients with early-stage TNBC; and Describe how to manage immune-related adverse events associated with neoadjuvant and adjuvant immunotherapy in early-stage TNBC.

Visit https://www.peervoice.com/HDT860 to view the entire programme with slides. After completing “Diana N. Ionescu, MD - Standardizing pCR Assessment in Early-Stage Breast Cancer: Evaluating Rationale, Methods, and Common Pitfalls”, participants will be able to: Review how to assess pathologic complete response (pCR) in patients with early-stage breast cancer following neoadjuvant therapy; Evaluate how to overcome common challenges in pCR assessment for patients with early-stage breast cancer following neoadjuvant therapy; and Outline strategies to optimize pCR assessment in early-stage breast cancer.

Visit https://www.peervoice.com/WPM860 to view the entire programme with slides. After completing “Giada Sebastiani, MD, FAASLD - Shedding Light on the Detection and Management of MASLD/MASH: Expert Insights to Improve Outcomes”, participants will be able to: Outline the epidemiology of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) and risk factors in patients with metabolic diseases; Describe recent guidelines for the screening of MASLD/MASH; Identify best practices to facilitate the early detection of MASLD/MASH in patients with metabolic diseases; Discuss the underlying pathophysiology and therapeutic targets in MASLD/MASH; and Formulate management strategies that may improve outcomes in patients with MASLD/MASH and comorbid conditions.

Visit https://www.peervoice.com/QTY860 to view the entire programme with slides. After completing “Shannon Salvador, MD, MSc, FRCSC - Advancing Frontline Endometrial Cancer Care: Translating the Latest Advances in Immunotherapy Plus Chemotherapy Regimens to Practice”, participants will be able to: Evaluate the clinical impact of first-line immunotherapy plus chemotherapy-based regimens in treating primary advanced or recurrent endometrial cancer; Identify patients who are eligible for first-line immunotherapy plus chemotherapy-based regimens for the treatment of primary advanced or recurrent endometrial cancer; and Outline personalized strategies to optimize outcomes for patients with primary advanced or recurrent advanced endometrial cancer on first-line immunotherapy plus chemotherapy combinations.

Visit https://www.peervoice.com/SAU860 to view the entire programme with slides. After completing “Robert J. Motzer, MD - Advanced Renal Cell Carcinoma: Clinical Advances in Approaches to Combination Therapy”, participants will be able to: Evaluate the available safety and efficacy data from trials examining current and emerging therapies, including combination regimens, in advanced renal cell carcinoma (RCC); Identify and assess adverse events (AEs) associated with combination therapy in patients with advanced RCC; and Apply recommended strategies and incorporate patient preferences in the management of AEs associated with combination therapy in advanced RCC.

Visit https://www.peervoice.com/FKD860 to view the entire programme with slides. After completing “Diana N. Ionescu, MD - To Target We Need to Test: Why and How to Identify Folate Receptor Alpha-Positive Ovarian Cancer”, participants will be able to: Use the clinical data for folate receptor alpha (FRɑ)-targeted therapies for ovarian cancer to evaluate the need for establishing FRɑ status; Describe the immunohistochemical characteristics of FRɑ-positive ovarian cancer; and Apply guideline recommendations for FRɑ testing and targeted treatment in patients with ovarian cancer.

Visit https://www.peervoice.com/YCX860 to view the entire programme with slides. After completing “Alon Altman, MD, FRCSC, CCPE - It Takes Two: Integrating Immunotherapy in Combination With Chemotherapy Into Recurrent or Primary Advanced Endometrial Cancer Care”, participants will be able to: Discuss current unmet needs in the frontline management of advanced endometrial cancer and the rationale for immunotherapy-chemotherapy combinations in this setting; Evaluate the clinical data for immunotherapy plus chemotherapy combinations for recurrent or primary advanced endometrial cancer; and Outline how to individualize treatment selection and manage safety concerns with available combination regimens to optimize patient outcomes.

Visit https://www.peervoice.com/CFP860 to view the entire programme with slides. After completing “Alessandro M. Vannucchi, MD, PhD - Not All JAKis Are Equal: What Can Trials and Real-World Evidence Tell Us About Optimal Treatment Approaches in Myelofibrosis?”, participants will be able to: Recall the results of clinical trials and real-world studies evaluating the effects of available Janus kinase (JAK) inhibitors on splenomegaly, symptoms, and cytopenias in patients with myelofibrosis (MF); and Formulate individualised treatment plans for patients with cytopenic MF considering the type and severity of the patient’s specific cytopenia(s).

Visit https://www.peervoice.com/QCE860 to view the entire programme with slides. After completing “Amrita Krishnan, MD - The Specifics of Bispecific Antibodies for Multiple Myeloma”, participants will be able to: Identify patients who may benefit from bispecific antibody therapy based on individual factors (such as disease characteristics or prior lines of treatment); and Implement evidence-based best practices in the recognition and management of adverse events associated with the use of bispecific antibodies in patients with multiple myeloma (MM).

Visit https://www.peervoice.com/WJH860 to view the entire programme with slides. After completing “Versha Banerji, MD, FRCPC - The Ties That Bind: Exploring the Role of Noncovalent BTK Inhibitors in CLL Treatment”, participants will be able to: Explain differences in mechanism of action between covalent BTK inhibitors and noncovalent BTK inhibitors; Discuss the clinical evidence for noncovalent BTK inhibitors; and Outline evidence-based strategies to integrate noncovalent BTK inhibitors into treatment paradigms for patients with chronic lymphocytic leukemia.